SOLIGENIX, INC. (SNGX): Nasdaq/NYSE listing notice — Nasdaq grants Soligenix continued listing subject to stockholders' equity compliance by March 31, 2023

SOLIGENIX, INC.

Nasdaq granted continued listing conditional on meeting minimum bid price by Feb 24 and stockholders' equity by March 31, 2023.
Soligenix satisfied the bid price condition as of Feb 24, 2023 (closing bid >= $1.00 for 10 consecutive sessions).
Company must demonstrate compliance with $2.5M stockholders' equity requirement by March 31, 2023; no assurance of success.
Original delisting notice (Dec 20, 2022) cited failure of both minimum bid price and stockholders' equity rules.
Hearing was held Feb 2, 2023; Panel granted extension with conditions.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SOLIGENIX, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

February 21, 2023, the Company received a letter (the “Continued Listing Letter”) from Nasdaq, stating that the Panel granted the Company’s request to continue its listing on Nasdaq, on the condition that (1) on February 24, 2023, the Company shall have demonstrated compliance with the Minimum Bid Price Requirement, by evidencing a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions; and (2) on or before March 31, 2023, the Company shall demonstrate compliance with the Stockholders’ Equity Requirement. The Continued Listing Letter is consistent with

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SOLIGENIX, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 21, 2023, the Company received a letter (the “Continued Listing Letter”) from Nasdaq, stating that the Panel granted the Company’s request to continue its listing on Nasdaq, on the condition that (1) on February 24, 2023, the Company shall have demonstrated compliance with the Minimum Bid Price Requirement, by evidencing a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions; and (2) on or before March 31, 2023, the Company shall demonstrate compliance with the Stockholders’ Equity Requirement. The Continued Listing Letter is consistent with

View on SEC.gov

Browse all listing & compliance notices →

SOLIGENIX, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-002040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.